Key result
Double-dose statin monotherapy shows no significant LDL-C benefit over moderate statin plus ezetimibe in diabetes.
Why the study?
Some patients with type 2 diabetes mellitus and dyslipidemia fail to achieve target low-density lipoprotein-cholesterol levels despite statin therapy, prompting trials comparing doubling the statin dose versus adding ezetimibe.
Does double-dose statin monotherapy compared to moderate-intensity statin combined with ezetimibe improve lipid profiles or safety outcomes in patients with type 2 diabetes mellitus?
Meta-Analysis (n=534)
Does double-dose statin monotherapy compared to moderate-intensity statin combined with ezetimibe improve lipid profiles or safety outcomes in patients with type 2 diabetes mellitus?
In patients with type 2 diabetes, high-intensity statin monotherapy provides comparable lipid-lowering and glycemic efficacy to moderate-intensity statin plus ezetimibe, but is associated with a significantly lower risk of serious clinical adverse events.
Answers are grounded in this paper and cite their sources.
Supports prioritizing high-intensity statin monotherapy for diabetic patients to minimize serious adverse events; challenges.
Cardiovascular disease is a leading cause of mortality, especially in individuals with type 2 diabetes mellitus and dyslipidemia. Despite adequate statin therapy, some patients fail to achieve the target low-density lipoprotein-cholesterol levels. Trials have compared doubling the statin dose with the addition of ezetimibe. A systematic literature search was performed using various databases. Forest plots were constructed for pooled analysis with statistical significance set at P < 0.05. Seven trials were included. Monotherapy showed no significant difference compared with dual therapy for low-density lipoprotein-cholesterol levels [mean difference (MD): −5.03; P = 0.37], high-density lipoprotein-cholesterol levels (MD: 0.01; P = 0.95), total cholesterol (MD: −2.38; P = 0.66), and triglycerides (MD: 5.37; P = 0.67) at follow-up compared to baseline. Monotherapy significantly reduced serious clinical adverse events (risk ratio: 0.21; P = 0.04), with no difference in treatment-related adverse effects, discontinuation due to treatment-related or overall adverse events.
No takes yet. Share an insight, caveat, or question.
Goyal et al. (2024) conducted a meta-analysis in Type 2 diabetes mellitus and hypercholesterolemia (n=534). Double-dose or high-intensity statin monotherapy vs. Moderate-intensity statin combined with ezetimibe dual therapy was evaluated on Change in low-density lipoprotein-cholesterol (LDL-C) levels at follow-up versus baseline (MD -5.03, 95% CI -16.09 to 6.03, p=0.37). Double-dose statin monotherapy showed no significant difference in LDL-C reduction compared to moderate-intensity statin with ezetimibe in diabetic patients.
Synapse has enriched 10 related papers. Consider them for comparative context: